Výsledky vyhledávání - "Léna Le Flem"

Monitoring plasma levels of factor Xa inhibitors: how, why and when?

Autor: Léna Le Flem, Jean Amiral, Meyer-Michel Samama, Jerard Seghatchian, Céline Guinet

Publikováno v: Expert Review of Hematology. 6:155-164

New oral anticoagulants are directed towards a single target, essentially factor Xa (FXa) or factor IIa. They do not require routine coagulation monitoring. However, in special clinical settings (emergency surgery, bleeding, thrombosis, control of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ca7c867551df41b6af0a95077a2316
https://doi.org/10.1586/ehm.13.11

Zobrazit plný text záznamu

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux

Autor: Jeanne Mendell, Céline Guinet, Léna Le Flem, Satoshi Kunitada, Meyer Michel Samama

Publikováno v: Thrombosis Research. 129:e77-e82

Introduction Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in Phase III development for prevention and treatment of thromboembolic disorders. Fondaparinux is an approved indirect FXa inhibitor. This study compared the effects of edoxaban and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb87de4659cb72ee34934505067018
https://doi.org/10.1016/j.thromres.2011.07.026

Zobrazit plný text záznamu

Effect of Argatroban versus Recombinant Hirudin on Tissue-Factor-Mediated Thrombin Generation: An in Vitro Study

Autor: Léna Le Flem, Céline Guinet, Meyer Michel Samama, François Depasse

Publikováno v: Seminars in Thrombosis and Hemostasis. 34:087-090

Argatroban, a synthetic chemical compound, and recombinant hirudin (r-hirudin) are both direct thrombin inhibitors. Their actions are reversible and irreversible, respectively. We studied the influence of these two anticoagulants on the thrombin gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::751340ee8e75e871c5a96fa88caba437
https://doi.org/10.1055/s-0028-1086087

Zobrazit plný text záznamu

Mutations in Promoter Region of Thrombomodulin and Venous Thromboembolic Disease

Autor: Jean-Noël Fiessinger, Joseph Emmerich, Martine Alhenc-Gelas, Sophie Gandrille, Léna Le Flem, Martine Aiach, Véronique Picard

Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1098-1104

Abstract —The present study was designed to analyze the thrombomodulin proximal promoter region spanning nucleotides −293 to −12 to search for polymorphisms that could modify thrombomodulin gene expression in patients with venous thromboembolic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7287e65e8014367404d26fc093072f5
https://doi.org/10.1161/01.atv.19.4.1098

Zobrazit plný text záznamu

Laboratory assessment of rivaroxaban: a review

Autor: Theodore E. Spiro, Jean Luc Martinoli, Genevieve Contant, Elisabeth Perzborn, Gabriele Rohde, Meyer Michel Samama, Céline Guinet, Yves Gourmelin, Léna Le Flem

Publikováno v: Thrombosis Journal

Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbb14c1e3b8e5f30bcbf7e92ab2ae69
https://pubmed.ncbi.nlm.nih.gov/23822763

Zobrazit plný text záznamu

Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

Autor: Léna Le Flem, Meyer Michel Samama, Jean-Marc Debue, Céline Guinet, Emmanuel Ninin

Publikováno v: Journal of thrombosis and thrombolysis. 35(2)

No routine coagulation laboratory test is recommended during rivaroxaban or dabigatran treatment. However measuring drug concentration and/or anticoagulant activity can be desirable in some special clinical settings, such as bleeding, thrombosis recu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::511b37ffa054f0988d756095fdfe7f54
https://pubmed.ncbi.nlm.nih.gov/23335022

Zobrazit plný text záznamu

Do new oral anticoagulants require laboratory monitoring? The clinician point of view

Autor: Meyer Michel Samama, Léna Le Flem, Céline Guinet

Publikováno v: Thrombosis research. 130

Although no laboratory monitoring is needed for new anticoagulants, the measurement of their activity is required in special clinical situations. Standardised tests have been developed for rivaroxaban and dabigatran which allow the measurement of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06894fdeb847a0c1c8fb84cc6d6b9259
https://pubmed.ncbi.nlm.nih.gov/23026675

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání